<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsFei Su, Jeffrey A. Sosman, Amaya Virós et al.|New England Journal of Medicine|2012Cited by 1k
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged SkinF. Stephen Hodi, David E. Fisher, Christopher L. Corless et al.|Journal of Clinical Oncology|2013Cited by 594
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV MelanomaAxel Hauschild, Ulrich Keilholz, Sanjiv S. Agarwala et al.|Journal of Clinical Oncology|2009Cited by 545
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S. Falchook, Leslie A. Fecher, Ngocdiep T. Le et al.|The Lancet Oncology|2012Cited by 541
Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsyPedram Gerami, David H. Lawson, Robert W. Cook et al.|Journal of the American Academy of Dermatology|2015Cited by 168